201608130015), Hebei University Science and technology research project (Grant No. H2019206637), China Scholarship Council (Grant No. 81801278), Natural Science Foundation of Hebei Province (Grant No. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the manuscript and its Supporting information files.įunding: This work was supported in the form of funding by Natural Science Foundation of China (Grant No. Received: OctoAccepted: FebruPublished: March 11, 2021Ĭopyright: © 2021 He et al. PLoS ONE 16(3):Įditor: Maria Cristina Vinci, Centro Cardiologico Monzino, ITALY (2021) Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data. The most commonly observed adverse reaction in the MSC treatment group was hypoglycemia (29.95%).Ĭitation: He J, Kong D, Yang Z, Guo R, Amponsah AE, Feng B, et al. Notably, there was no significant difference in the incidence of adverse events between MSCs treatment group and control group. However, as for fasting C-peptide levels, the estimated pooled MD showed that there was no significant increase in MSCs treatment group compared with that in control group. Additionally, HbA1c reduced more significantly in MSC treatment group than in control group at the end of follow-up. The MSCs treatment group showed a significant decrease in hemoglobin (Hb) A1c after treatment. Meta-analysis results showed that there were no significant differences in the reduction of fasting plasma glucose (FPG) compared to the baseline and the control group. Seven RCTs were eligible for analysis, including 413 participants. The retrieval time was from establishment of these databases to January 4, 2020. PubMed, Web of Science, Ovid, the Cochrane Library and CNKI were searched. The aim of this study was to systematically review the evidence from RCTs and, where possible, conduct meta-analyses to provide a reliable numerical summary and the most comprehensive assessment of therapeutic efficacy and safety with MSCs in diabetes.
0 kommentar(er)
